Single-cell genomics details the maturation block in BCP-ALL and identifies therapeutic vulnerabilities in DUX4-r cases.

Autor: Thorsson H; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Henningsson R; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Puente-Moncada N; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Peña-Martínez P; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Sjöström L; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Ågerstam H; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden., Sandén C; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Rissler M; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Castor A; Childhood Cancer Center, Skåne University Hospital, Lund, Sweden., Marquart H; Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.; Department of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Modvig S; Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.; Department of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Paulsson K; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Pronk CJ; Childhood Cancer Center, Skåne University Hospital, Lund, Sweden., Schmiegelow K; Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.; Department of Pediatrics and Adolescent Medicine, The Juliane Marie Centre, University Hospital Rigshospitalet, Copenhagen, Denmark., Hyrenius-Wittsten A; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Orsmark-Pietras C; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden., Lilljebjörn H; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Fioretos T; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden.

Publikováno v: Blood [Blood] 2024 Sep 26; Vol. 144 (13), pp. 1399-1411.

The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML.

Autor: von Palffy S; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Thorsson H; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Peña-Martínez P; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Puente-Moncada N; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Sandén C; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Blom AM; Department of Translational Medicine, Lund University, Malmö, Sweden., Henningsson R; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Juliusson G; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden., King B; Department of Translational Medicine, Lund University, Malmö, Sweden., Landberg N; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Lazarevic V; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden., Orsmark-Pietras C; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Rissler M; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Rissler V; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Ågerstam H; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Järås M; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Lilljebjörn H; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden., Fioretos T; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Publikováno v: Blood advances [Blood Adv] 2023 Apr 11; Vol. 7 (7), pp. 1204-1218.

IL1RAP is expressed in several subtypes of pediatric acute lymphoblastic leukemia and can be used as a target to eliminate ETV6::RUNX1 -positive leukemia cells in preclinical models.

Autor: Ågerstam H; Division of Clinical genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden; Department of Clinical Genetics and Pathology, Office for Medical Services, Region Skåne, Lund. helena.agerstam@med.lu.se., Lilljebjörn H; Division of Clinical genetics, Department of Laboratory Medicine, Lund University, Lund., Rissler M; Division of Clinical genetics, Department of Laboratory Medicine, Lund University, Lund., Sandén C; Division of Clinical genetics, Department of Laboratory Medicine, Lund University, Lund., Fioretos T; Division of Clinical genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden; Department of Clinical Genetics and Pathology, Office for Medical Services, Region Skåne, Lund. thoas.fioretos@med.lu.se.

Publikováno v: Haematologica [Haematologica] 2023 Feb 01; Vol. 108 (2), pp. 599-604. Date of Electronic Publication: 2023 Feb 01.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

MAXIMISE – A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of secukinumab in patients with active psoriatic arthritis and axial skeleton involvement

Autor: Baraliakos, X, Rissler, M, Perella, C

Publikováno v: 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20170906-20170909; Stuttgart; DOCSpA.14 /20170904/

Background: The purpose of this study is to demonstrate the efficacy and safety of secukinumab in the management of axial manifestations in patients with psoriatic arthritis (PsA) who have failed to respond to at least 2 NSAIDs over a 4-week period,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4256009a6122aa6a69d7ac67d2e83804